Literature DB >> 25090988

Targets for medical therapy to limit abdominal aortic aneurysm progression.

Theophilus I Emeto, Sai-Wang Seto, Jonathan Golledge1.   

Abstract

Abdominal aortic aneurysm (AAA) is an important cause of mortality in older adults. Most AAAs are asymptomatic and screening programs have been introduced to identify AAAs at an early stage in some countries. There is currently no accepted therapy for early stage or small AAAs, which are frequently identified by such programs. In this review, we discuss work underway to identify targets for medical treatments to limit progression of small AAAs. Specifically we discuss studies, which have examined the potential of targeting inflammation, proteolysis, the renin-angiotensin system, the coagulation system and sex hormones as approaches to limiting AAA pathogenesis. As yet, none of the treatment targets have translated into an agent, which can effectively reduce AAA progression in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25090988     DOI: 10.2174/1389450115666140804155036

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  12 in total

Review 1.  Sex differences in abdominal aortic aneurysms.

Authors:  Austin C Boese; Lin Chang; Ke-Jie Yin; Y Eugene Chen; Jean-Pyo Lee; Milton H Hamblin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-19       Impact factor: 4.733

Review 2.  Reactive oxygen species: key regulators in vascular health and diseases.

Authors:  Qishan Chen; Qiwen Wang; Jianhua Zhu; Qingzhong Xiao; Li Zhang
Journal:  Br J Pharmacol       Date:  2017-07-11       Impact factor: 8.739

3.  New Mouse Model of Abdominal Aortic Aneurysm: Put Out to Expand.

Authors:  Stoyan N Angelov; Jay Zhu; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11       Impact factor: 8.311

4.  Immunohistochemical analysis of the natural killer cell cytotoxicity pathway in human abdominal aortic aneurysms.

Authors:  Irene Hinterseher; Charles M Schworer; John H Lillvis; Elizabeth Stahl; Robert Erdman; Zoran Gatalica; Gerard Tromp; Helena Kuivaniemi
Journal:  Int J Mol Sci       Date:  2015-05-18       Impact factor: 5.923

5.  UCP-2 is involved in angiotensin-II-induced abdominal aortic aneurysm in apolipoprotein E-knockout mice.

Authors:  Peng Yan; Ken Chen; Qiang Wang; Dachun Yang; Yongjian Yang
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

Review 6.  Use of Nanoparticles As Contrast Agents for the Functional and Molecular Imaging of Abdominal Aortic Aneurysm.

Authors:  Theophilus I Emeto; Faith O Alele; Amy M Smith; Felicity M Smith; Tammy Dougan; Jonathan Golledge
Journal:  Front Cardiovasc Med       Date:  2017-03-23

7.  Chinese Herbal Medicine as a Potential Treatment of Abdominal Aortic Aneurysm.

Authors:  Sai Wang Seto; Dennis Chang; Hosen Kiat; Ning Wang; Alan Bensoussan
Journal:  Front Cardiovasc Med       Date:  2018-04-20

8.  Hypoperfusion of the Adventitial Vasa Vasorum Develops an Abdominal Aortic Aneurysm.

Authors:  Hiroki Tanaka; Nobuhiro Zaima; Takeshi Sasaki; Masaki Sano; Naoto Yamamoto; Takaaki Saito; Kazunori Inuzuka; Takahiro Hayasaka; Naoko Goto-Inoue; Yuki Sugiura; Kohji Sato; Hirona Kugo; Tatsuya Moriyama; Hiroyuki Konno; Mitsutoshi Setou; Naoki Unno
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

9.  The role of IL-6 in pathogenesis of abdominal aortic aneurysm in mice.

Authors:  Michihide Nishihara; Hiroki Aoki; Satoko Ohno; Aya Furusho; Saki Hirakata; Norifumi Nishida; Sohei Ito; Makiko Hayashi; Tsutomu Imaizumi; Yoshihiro Fukumoto
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

10.  Involvement of B Cells, Immunoglobulins, and Syk in the Pathogenesis of Abdominal Aortic Aneurysm.

Authors:  Aya Furusho; Hiroki Aoki; Satoko Ohno-Urabe; Michihide Nishihara; Saki Hirakata; Norifumi Nishida; Sohei Ito; Makiko Hayashi; Tsutomu Imaizumi; Shinichi Hiromatsu; Hidetoshi Akashi; Hiroyuki Tanaka; Yoshihiro Fukumoto
Journal:  J Am Heart Assoc       Date:  2018-03-15       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.